Two new PET imaging agents have been developed to identify the histamine H3 receptor, which regulates learning, memory, and sleep. These novel tracers show high brain uptake, excellent specificity, and improved in vivo stability.
A new PET imaging technique has successfully visualized three radiotracers in a single scan, enabling a more comprehensive molecular profile of disease. This innovation offers the potential to deliver greater precision in both diagnosis and therapeutic assessment, particularly for complex diseases like cancer.
Advanced software is used to measure radiation dose distribution throughout the body, ensuring patient safety and tailoring treatments. Post-therapy imaging helps identify complications and guide clinical decisions, ultimately optimizing treatment outcomes and protecting patients.
Researchers found that low blood flow at rest may predict heart failure or death, while low stress flow may indicate heart attack risk. A new PET scan method also showed promise for Alzheimer's detection with high accuracy and minimal discomfort.
A novel immuno-PET/CT imaging technique has identified a potent biomarker for nasopharyngeal cancer (NPC), CD70, which is highly expressed in NPCs. The technique showed 100% detection rate of primary tumors and 93% detection rate of local lymph node metastasis in patients with early-stage disease.
New radioimmunotherapy approaches show promise against advanced breast cancer and prostate cancer. Additionally, new imaging tools enhance cancer detection and diagnosis, while a proposed standard improves lesion interpretation. Cost-effectiveness studies also support novel therapies for rare digestive cancers.
A newly developed molecular imaging technique can identify multiple subtypes of triple-negative breast cancer, improving diagnostic capacity. The approach targets extra domain A of fibronectin, a stable protein in the tumor stromal environment abundantly expressed in breast cancer.
Researchers studied obesity's impact on breast cancer, linked imaging patterns to lung disease survival, and tracked hidden inflammation in COVID-19 patients using advanced PET imaging techniques.
New studies explore peptide receptor radionuclide therapy, targeted radiation for prostate cancer, and neuroendocrine tumor treatment. Targeted radiation boosts survival in colorectal liver cancer and bone metastases, while a new PET imaging tracer shows promise for detection.
A new combination therapy pairing radiopharmaceutical 177Lu-DOTATATE with DNA-repair blocker olaparib has been deemed feasible and tolerable for neuroendocrine cancer patients. Eighteen patients received the combined therapy, resulting in a 69% disease control rate at six months.
Scientists have developed a novel pretargeting system to boost cancer imaging using DARPin G3, which achieves specific tumor targeting with reduced kidney and liver uptake. GRPR is emerging as a powerful tool for both imaging and treatment in various cancers, offering personalized cancer care across multiple tumor types.
Scientists have developed a new PET imaging compound to visualize key enzymes in mental health, enabling multiple same-day scans. Additionally, researchers have discovered that PET scans can detect not only HER2-positive but also HER2-low breast cancer lesions.
Researchers have developed new imaging tools to visualize protein changes in Alzheimer's, heart and lung issues in long COVID patients, and a common marker in nasopharyngeal cancer. A first-in-human trial tests a next-generation radiopharmaceutical for advanced prostate cancer.
Researchers have discovered important differences in how a targeted therapy behaves in the body over time, allowing for more tailored treatment strategies. A new PET/CT scanner also shows promise for accurate imaging with dramatically reduced exposure, especially for sensitive patients like children or those needing repeated scans.
A new study finds that radioiodine therapy significantly increases relative survival rates in differentiated thyroid cancer patients, with benefits observed across low-, intermediate-, and high-risk subgroups. The treatment reduces recurrence rates and improves long-term survival in high-risk groups, while also showing promise for low-...
A novel radiolabeled antibody targeting the cancer antigen IL13Rα2 has been developed with high specificity for diagnosing and treating solid tumors. The antibody was effective in delineating malignancies at a low injected mass dose, making it a potential candidate for radioimmunotherapy applications.
Researchers have developed novel imaging agents targeting shared proteins in triple-negative breast cancer tumors, successfully highlighting various tumor types using PET/CT scans. Additionally, a new brain imaging technique shows promise in identifying complex brain diseases like progressive supranuclear palsy and corticobasal degener...
The SNMMI Mars Shot Research Fund has awarded a $100,000 fellowship to Dr. Randy Ye for his research on FAPI PET imaging for detecting invasive lobular carcinoma. The study aims to assess the ability of FAPI PET and FDG PET to detect tumors and evaluate its impact on patient care.
Researchers discovered rare cases of prostate cancer spreading to the testicles using advanced PSMA PET/CT scans, changing how doctors monitor recurring prostate cancer. A new ultra-low-dose PET scanning method reduced radiation exposure without compromising diagnostic image quality in cancer and metabolic imaging.
Two new studies published in The Journal of Nuclear Medicine explore innovative approaches to treating melanoma with radiation therapy and enhancing brain PET imaging. A third study validates an AI network for brain tumor imaging, demonstrating promising results.
A novel PET imaging approach has effectively quantified the COX-2 enzyme in human brains, opening doors for its use in clinical settings for various brain disorders. This breakthrough could lead to earlier disease detection and monitor disease progression with anti-inflammatory treatments.
New research published in The Journal of Nuclear Medicine explores ways to improve the diagnosis and treatment of metastatic breast cancer using Ga-NeoB PET/CT. Additionally, studies examine the potential of paraaminohippurate to reduce kidney toxicity during radiopharmaceutical therapy.
Researchers have confirmed a neurobiochemical link between dopamine and cognitive flexibility through PET imaging, showing increased dopamine production with cognitively demanding tasks. This finding may lead to the development of more precise treatment strategies for neurological and psychiatric disorders.
Researchers explore new techniques to improve prostate cancer diagnosis and treatment, including dual-target PET/CT for enhanced lymph node staging and novel PSMA-targeted radioligands for more precise tumor targeting.
A new PET radiotracer effectively visualizes Nectin-4, a biomarker found in triple-negative breast cancer (TNBC), with the potential to improve clinical outcomes. Researchers developed a series of Nectin-4-targeted radiotracers and evaluated their efficacy in detecting TNBC.
A new PET tracer has been developed to visualize intact nerve connections in the spinal cord, which may indicate a better chance of recovery. This breakthrough has the potential to help diagnose injuries more precisely, monitor recovery, and evaluate the effectiveness of new therapies.
Next-generation tau radiotracers demonstrate higher binding to Alzheimer's disease brain tissue and greater selectivity than existing imaging agents. This could lead to improved diagnosis and staging of the disease, as well as better outcomes in clinical trials.
The Society of Nuclear Medicine and Molecular Imaging has issued a new procedure standard/practice guideline for the use of fibroblast activation protein (FAP) PET, outlining indications, imaging procedures, and quality control/quality assurance procedures. The guideline aims to deliver diagnostic efficacy and study quality for patients.
A new PET approach has detected early signs of tissue remodeling in patients with pulmonary arterial hypertension, providing an early marker for disease progression. This could pave the way for more personalized management and timely interventions to improve patient prognosis.
A novel radiotracer has accurately identified a crucial cancer biomarker, Trop2, found in various types of cancer. The radiotracer, <sup>18</sup> F-AlF-RESCA-T4, enables precise visualization of Trop2 expression and can differentiate lung inflammation from cancer.
Researchers found that intraarterial peptide receptor radionuclide therapy is safe and effective for patients with advanced meningioma, offering improved radiologic and clinical disease control compared to intravenous PRRT. The treatment was well-tolerated, with no additional toxicity, and showed promising results in disease control.
The Centers for Medicare & Medicaid Services (CMS) has announced a significant adjustment to the Hospital Outpatient Prospective Payment System (HOPPS), unbundling diagnostic radiopharmaceuticals costing above $630. This change aims to improve access to life-saving nuclear medicine scans, providing critical insights for patient treatme...
A novel PET/CT technique has been developed to detect neuroblastoma in children with high sensitivity and short scan time, eliminating the need for sedation or anesthesia. The new technique uses a novel tracer and next-generation scanner, resulting in improved diagnostic accuracy and reduced radiation exposure.
A new fluorescent imaging probe can non-invasively measure loss of smell, potentially eliminating biopsies used to diagnose anosmia. The tool targets the olfactory nerve, showing promise for diagnosing and treating smell disorders in patients.
A newly developed granzyme B PET imaging method can non-invasively detect IBD and provide a real-time picture of active inflammation. This technology could guide personalized patient management strategies and monitor treatment efficacy.
Researchers found that lower doses of radiopharmaceutical therapy approaches for metastatic castrate-resistant prostate cancer were just as effective as the standard dose, with better tolerability among patients. The study showed improved PSA response rates and comparable median overall survival in both groups.
The 2024 SNMMI Annual Meeting showcased the latest advancements in theranostics, artificial intelligence, and other fields, with over 130 continuing education sessions and 1,000 posters. The meeting also featured unique opportunities for attendee engagement and connection.
A new chelator, L804, reduces off-target toxicity in PSMA radiopharmaceutical therapy by improving the bond between radioactive metal ions and targeting antibodies. This makes the therapy safer and more effective for patients.
Researchers have developed a novel approach to treat colorectal cancer using simultaneous delivery of alpha- and beta-radionuclides, significantly reducing side effects. The therapy, known as pretargeted dual-isotope radionuclide therapy, has been shown to be effective in inducing tumor shrinkage and cures.
A comparative study between FAPI and 18F-FDG PET/CT shows that FAPI PET/CT is more accurate in staging newly diagnosed breast cancer patients, with 19.8% being restaged due to its high sensitivity. This could lead to optimized management plans and improved patient outcomes.
A new ultra-low dose imaging method with long axial field-of-view PET scanners can generate quantitative PET images without the need for accompanying CT scans, reducing radiation exposure to patients. The technique reduces the total effective dose by approximately 50 times lower than the standard PET dose.
Dr. Michael J. Evans has been named the 2024 recipient of the prestigious Sam Gambhir Trailblazer Award, recognizing his exceptional contributions to nuclear medicine and molecular imaging. He is honored for his groundbreaking work in biomarker discovery and radiopharmaceutical development.
Cathy Sue Cutler, Ph.D., FSNMMI, was elected SNMMI President to continue supporting the Facilitating Innovative Nuclear Diagnostics (FIND) Act. She aims to improve workforce development, create training opportunities, and educate the public on nuclear medicine.
Researchers developed a novel radiotracer that generates high-quality images of cardiac amyloidosis, a condition referred to as the Alzheimer's disease of the heart. The technetium-99m labeled variant of the pan-amyloid reactive peptide p5+14 showed significant uptake in patients with amyloid cardiomyopathy.
Dr. David M. Goldenberg, MD, has received the 2024 Benedict Cassen Prize for his pioneering work in monoclonal antibodies and immunotherapy, leading to significant advances in nuclear medicine science. His contributions have resulted in personalized therapy for cancer patients with a new generation of agents.
The NeuroEXPLORER PET scanner offers exceptional brain PET images with ultra-high sensitivity and resolution, showcasing focal uptake in specific brain nuclei. This technology has the potential to spur advances in treating conditions like Alzheimer's disease, Parkinson's disease, and mental illnesses.
SNMMI has elected Heather Jacene, MD, as Vice President-Elect, aiming to strengthen the organization through active listening and collaborations. Jacene's research focuses on cancer therapy response monitoring using novel tracers, and she aims to break down barriers in radiopharmaceutical availability.
Jean-Luc C. Urbain, MD, PhD, FASNC, has been named president-elect of SNMMI, focusing on radiopharmaceutical theranostics integration into clinics to benefit patients. He aims to increase the society's visibility, membership, and financial support through outreach to underrepresented professionals.
A novel AI approach can accurately detect six different types of cancer on whole-body PET/CT scans, automatically quantifying tumor burden. The tool provides a framework for identifying robust predictive biomarkers and enabling early detection and treatment of cancer.
Research suggests that using hearing aids can help mitigate the acceleration of brain metabolism decline in individuals with mild cognitive impairment. The study found significant annual metabolic decline in frontal cortical regions among those with untreated hearing loss, whereas those with treated hearing aids experienced no such dec...